What is Abcellera Biologics Inc?
engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.16B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 3122,778 shares $1.4M |
| 3-6months | 0 | 393,587 shares $975k |
| 6-9months | 0 | 4278,057 shares $952k |
| 9-12months | 0 | 150,000 shares $178k |